Akut lebensbedrohliche Herzrhythmusstörungen

Herzrhythmusstörungen sind ein häufiges Phänomen und können in der Akutsituation eine Herausforderung für die behandelnden Ärzte darstellen. Der Beitrag stellt die verschiedenen bradykarden und tachykarden Herzrhythmusstörungen und deren Therapie vor und gibt praktische Hinweise zur Diagnostik.

Abstract

Cardiac arrhythmias are a common phenomenon and can be a challenge for the treating physicians in the acute situation. The article presents the different bradycardic and tachycardic cardiac arrhythmias and their treatment with practical advices for diagnosis.

Schlüsselwörter

Herzrhythmusstörungen - Reanimation - medikamentöse antiarrhythmische Therapie - bradykarde Herzrhythmusstörungen - tachykarde Herzrhythmusstörungen

Key words

cardiac arrhythmias - antiarrhythmic medical treatment - bradycardic cardiac arrhythmias - tachycardic cardiac arrhythmias)

Publication History

Article published online:
15 June 2021

• Literatur

• 1 Lewalter T, Luderitz B. Arzneimitteltherapie der Herzrhythmusstörungen. Internist 2000; 41 (Suppl. 01) S22-S33
• 2 Sandroni C, Nolan J. European Resuscitation Counsil. ERC 2010 Guidelines for adult and pediatric Resuscitation: summary of major changes. Minerva Anestesiol 2011; 77: 220-226
• 3 Nolan JP, Cariou A. Post-resuscitation care: ERC-ESICM guidelines 2015. Intensive Care Med 2015; 41: 2204-2206 DOI: 10.1007/s00134-015-4094-5.
• 4 Monsieurs KG, Nolan JP, Bossaert LL. et al European Resuscitation Council Guidelines for Resuscitation 2015: section 1. Executive summary. Resuscitation 2015; 95: 1-80 DOI: 10.1016/j.resuscitation.2015.07.038.
• 5 Barstow C, McDivitt JD. Cardiovascular disease update: bradyarrhythmias. FP Essent 2017; 454: 18-23
• 6 Priori SG, Blomstrom-Lundqvist C, Mazzanti A. et al 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867 DOI: 10.1093/eurheartj/ehv316.
• 7 Ortiz M, Martin A, Arribas F. et al Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J 2017; 38: 1329-1335
• 8 Larrey D, Pessayre D, Duhamel G. et al Prolonged cholestasis after ajmaline-induced acute hepatitis. J Hepatol 1986; 2: 81-87
• 9 deSouza IS, Martindale JL, Sinert R. Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review. Emerg Med J 2015; 32: 161-167 DOI: 10.1136/emermed-2013-202973.
• 10 Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag 2010; 6: 465-472
• 11 Deneke T, Israel CW. Ischämiediagnostik und Revaskularisation bei Patienten mit ventrikulären Tachyarrhythmien. Herzschrittmacherther Elektrophysiol 2017; 28: 157-161 DOI: 10.1007/s00399-017-0515-1.
• 12 Kudenchuk PJ, Leroux BG, Daya M. et al Antiarrhythmic drugs for nonshockable-turned-shockable out-of-hospital cardiac arrest: The ALPS Study (amiodarone, lidocaine, or placebo). Circulation 2017; 136: 2119-2131 DOI: 10.1161/CIRCULATIONA-HA. 117.028624.